Dextrorebellazole sodium, a new drug for three kinds of peptic ulcer, was accepted

According to the website of the State Food and Drug Administration (CFDA) on April 1, the three kinds of drugs for clinical application of arcacom, i.e dextrorebellazole sodium for raw materials and dextrorebellazole sodium for injection, were accepted At present, there is no such product on the market in China, and only two domestic enterprises apply for the product D-rabeprazole sodium is used in the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis and so on It was first developed by emcure pharmaceutical company in India and listed in India in September 2007 Now it has been listed in Europe and America, but it has not yet entered China CFDA website also has no application for import registration of this product The data showed that, compared with omeprazole and rabeprazole, D-rabeprazole has stronger inhibitory effect on enzyme, and the inhibition can be restored; it has less effect on plasma gastrin level; it has higher effect on heartburn and gastric reflux, and the symptom relief time is significantly faster than the former two According to CFDA, at present, only two domestic pharmaceutical companies have applied for the clinical approval documents of dextrorebellazole sodium, among which Nanjing Huawei pharmaceutical applied for dextrorebellazole sodium and enteric coated tablets in 2012, Hunan Mingrui pharmaceutical applied for dextrorebellazole sodium and dextrorebellazole sodium for injection in February this year Aosaikang is mainly engaged in the production and sales of digestive and anti-tumor drugs, and is the leader of digestive drugs Aosaikang chairman Chen Qingcai once said that the company has its own brand foundation, channels and experience in the field of digestion In the future, the research and development direction will still focus on digestion and enrich the company's product line.